The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $189.42

Today's change+0.33 +0.17%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $189.42

Today's change+0.33 +0.17%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Jazz Pharmaceuticals PLC up (U.S.)$0.33

Jazz Pharmaceuticals PLC closed up Friday by (U.S.)$0.33 or 0.17% to (U.S.)$189.42. Over the last five days, shares have gained 1.20% and 15.69% year to date. Shares have outperformed the S&P 500 by 21.06% during the last year.

Key company metrics

  • Open(U.S.) $188.90
  • Previous close(U.S.) $189.09
  • High(U.S.) $190.32
  • Low(U.S.) $187.46
  • Bid / Ask-- / --
  • YTD % change+15.69%
  • Volume307,854
  • Average volume (10-day)395,522
  • Average volume (1-month)637,831
  • Average volume (3-month)679,427
  • 52-week range(U.S.) $120.38 to (U.S.) $190.48
  • Beta0.73
  • Trailing P/E286.97×
  • P/E 1 year forward19.40×
  • Forward PEG0.99×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.66
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.10%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue328307291247
Total other revenue--------
Total revenue328307291247
Gross profit299280261216
Total cost of revenue29273131
Total operating expense198249217314
Selling / general / administrative10494101106
Research & development259720145
Depreciation / amortization32313331
Interest expense (income), net operating--------
Unusual expense (income)9033--
Other operating expenses, total--------
Operating income1305874-67
Interest income (expense), net non-operating-17-15-11-10
Gain (loss) on sale of assets--------
Other--------
Income before tax1155063-77
Income after tax822644-94
Income tax, total34241917
Net income822644-93
Total adjustments to net income--------
Net income before extra. items822644-93
Minority interest0001
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items822644-93
Inc. avail. to common incl. extra. items822644-93
Diluted net income822644-93
Dilution adjustment------0
Diluted weighted average shares72636259
Diluted EPS excluding extraordinary itemsvalue per share1.130.410.70-1.58
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.290.261.13-1.38